OECD'S SPHeP MODELS
A TOOL TO INFORM STRATEGIC PLANNING IN PUBLIC HEALTH
The family of OECD models to support Strategic Public Health Planning (SPHeP) are designed to inform and support the decision making process in countries at all levels of income. Our models produce evidence that can guide policy decisions on how to ensure that resources spent on public health policy actions will produce the greatest health outcomes and economic benefits. They are designed to generate data on how to prevent, manage and control key public health threats. This includes the vast majority of non-communicable diseases, injuries and mental health problems, as well as emerging threats in the field of communicable diseases.

The OECD has developed two advanced system-modelling tools to cover all the areas of public health:

- A microsimulation model, which covers all the key threats related to non-communicable diseases. These include diabetes, cancers and cardiovascular diseases, in addition to injuries and mental health issues, as well as key risk factors such as harmful alcohol consumption, unhealthy diet, physical inactivity and tobacco use. In total, the model accounts for more than 26 diseases and 6 risk factors, which represent the vast majority of the burden of disease.
- An agent-based model, to simulate dynamics specific to communicable diseases. So far, the OECD is applying this methodology to antimicrobial resistance (AMR) and COVID-19, but the framework can be broadly applicable to all communicable diseases.

OECD work covers more than 50 countries - all the 37 OECD member countries, the other non-OECD EU and G20 countries, as well as other key partners of the OECD - accounting for more than 4.7 billion people (over 60% of the world’s population) and nearly 80% of the world economy (Figure 1).

The models help policy-makers respond to the following questions:

- What would be the investment needed to implement or scale up a specific public health programme?
- What would be the impact of this intervention in terms of population health and healthcare expenditure? (e.g. Figure 2)
- What would be the effects of the new programme on labour force productivity and the economy (i.e. GDP)?
- What is the return on investment of the policy action and its distributional impact?
- How long will it take to produce the desired effects?

As part of work on obesity, the OECD SPHeP-NCD model was used to evaluate the impact of a reformulation programme to reduce calories by 20% in foods high in sugar, salt, calories and saturated fat. This target could be achieved by implementing a mix of policies such as raising awareness in the population, using economic incentives to promote reformulation and procurement policies. While a global deal to reduce calorie content in relevant food by 20% would not address all the causes underpinning the obesity epidemic, it would have a significant health and economic impact.

Figure 2: The impact of a 20% reduction in calorie content in energy dense food across 42 countries, according to the SPHeP-NCD model.

The models can easily be adapted to cover any country in the world.

Figure 1: Countries covered by the OECD SPHeP models by WHO Region.

<table>
<thead>
<tr>
<th>Region</th>
<th>AMRO</th>
<th>AFRO</th>
<th>EMRO</th>
<th>EURO</th>
<th>WPRO</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td></td>
<td></td>
<td>South Asia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Russia</td>
<td></td>
<td></td>
<td>Norway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iceland</td>
<td></td>
<td></td>
<td>Switzerland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td></td>
<td></td>
<td>Turkey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel</td>
<td></td>
<td></td>
<td>United Arab Emirates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td></td>
<td></td>
<td>Argentina</td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td></td>
<td></td>
<td>India</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td></td>
<td></td>
<td>Indonesia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Australia</td>
<td></td>
<td></td>
<td>Malaysia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td></td>
<td></td>
<td>Philippines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korea</td>
<td></td>
<td></td>
<td>Vietnam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peru</td>
<td></td>
<td></td>
<td>Mexico</td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td>Brazil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Argentina</td>
<td></td>
<td></td>
<td>Brazil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chile</td>
<td></td>
<td></td>
<td>Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td></td>
<td></td>
<td>Colombia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costa Rica</td>
<td></td>
<td></td>
<td>Costa Rica</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td></td>
<td></td>
<td>Mexico</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peru</td>
<td></td>
<td></td>
<td>Peru</td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td>USA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: OECD analyses based on the OECD SPHeP-NCD model.
While the two models are different in their structure, they share the same philosophy and require similar types of data as input. The models generate synthetic life stories (from birth to death), in which each simulated individual is ascribed a set of characteristics and risk factors, in order to predict the consequent disease outcomes. Simulated individuals fully replicate the population of a given country in terms of:

- Risk factor profile including lifestyles (e.g. diet, physical activity and alcohol/tobacco use) and physiological risk factors (e.g. overweight);
- Epidemiology including incidence of chronic diseases and infection, probability of dying in the case of adverse outcomes, as well as consequences or disability following a disease;
- Use of healthcare services including, for example, probability of hospitalisation and length of stay as well as the disease-specific healthcare expenditure;
- Participation to the labour force including, for example, probability of being employed and average wage;
- Demography including gender and age structure as well as life expectancy.

Our models are designed to support countries in allocating resources and in evaluating the impact of public health policies. All countries can benefit from this modelling work, including:

- Countries that are designing a new public health policy and that would like to assess its likely impact, implementation cost and return on investment;
- Countries that have implemented a policy, or a comprehensive policy package in the past, and would like to evaluate the health and economic impact of their reform once sufficient data have been collected;
- Countries that would like to strengthen their strategy to deal with a specific public health issue and are interested in comparing alternative options to identify the most effective and efficient investment.
Model functioning and outputs

Data to model all these dimensions are retrieved from international datasets providing cross-country comparable data. In addition to the OECD dataset, other common sources of data include datasets hosted by the World Bank, the World Health Organization, the International Agency for Research on Cancer, the European Centre for Disease Prevention and Control, and the Institute for Health Metrics Evaluation. However, it is also possible to use different inputs (e.g. from national health surveys), should a country prefer to do so.

The models use this input data, and through the use of standard algorithms, project a ‘business as usual’ scenario over a period of, usually, 30 years (e.g. between 2020 and 2050) – (Figure 3). In a second step, the models are run again after the implementation of the policy intervention - for example, to evaluate the impact of a mass media campaign aiming to increase physical activity to tackle chronic diseases at the population level, or an intervention to enhance hygiene in hospitals to prevent hospital-acquired infections. The comparison between the two scenarios generates the impact of the intervention.

The models produce a rich set of outputs providing useful information on all key health and economic perspectives. In addition, the OECD SPHeP models can be linked to the OECD long-term macroeconomic model to assess how policies impact GDP and fiscal pressure (i.e. the government primary revenue needed to stabilise the public debt). The OECD SPHeP models can produce analyses on:

- Health outcomes: life years, disability-adjusted life years (DALYs), life expectancy, premature mortality, disease cases;
- Healthcare expenditure: total healthcare expenditure and disease-specific expenditure;
- Labour force participation and productivity: absenteeism, presenteeism, early retirement or sick leaves due to ill-health;
- Gross domestic product (GDP) and fiscal pressure (i.e. the government primary revenue needed to stabilise the public debt).

Diseases covered by the models

The SPHeP-NCD model accounts for over 26 diseases, including ischaemic heart disease, diabetes mellitus, cardiovascular disease, chronic kidney disease, low back and neck pain, hypertensive heart disease, colon and rectum cancer, esophageal cancer, liver cancer, kidney and pancreatic cancer, cirrhosis, alcohol use disorder, road injuries, unintentional injuries, self-harm, interpersonal violence, breast cancer, nasopharynx cancer, stroke, chronic obstructive pulmonary disease, lower respiratory infections, atrial fibrillation, rheumatoid arthritis, depression and dementia.

The SPHeP-AMR model includes 8 bacteria and 17 antibiotic-bacterium: Acinetobacter spp., Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis and Enterococcus faecium. Moreover, the OECD is currently extending the model to also include Shigella, Salmonella, Campylobacter, and Mycobacterium tuberculosis.

A new SPHeP-COVID model is also being developed.
Between 2015 and 2050, and after adjusting for differences in prices across countries through the PPP approach, AMR would cost approximately USD PPP 3.5 billion per year to the healthcare services of the 33 countries included in the analysis;

Many interventions to promote prudent use of antibiotics and to enhance hygiene in hospitals cost 0.3 to 2.7 USD PPP per capita per year in many OECD countries (Figure 4), and are affordable in countries at lower levels of income;

Investing 2 USD PPP per capita per year in a comprehensive package encompassing public health measures would avoid approximately 47,000 deaths per year in OECD countries;

The public health package could pay for itself within just one year and end up saving USD 4.8 billion of dollars per year in OECD countries.

**European Commission**

OECD models are often used to inform recommendations by other Intergovernmental Organisations on effective and cost-effective policies to tackle top public health threats. For example, the European Court of Auditors (ECA) used outputs from the OECD SPHeP-AMR model to inform its recommendations to EU Member States and the European Commission on antimicrobial resistance (AMR).

Drawing on the findings from the OECD work, the ECA issued a number of recommendations supporting the wider implementation of the policy options assessed with the OECD SPHeP-AMR model to tackle inappropriate use of antibiotics in hospitals and other healthcare settings. In particular, ECA used the economic assessment carried out by the OECD to stress the economic case to upscale action on AMR.

The project was co-funded by the European Commission.
The OECD SPHeP-NCD model is used to calculate the impact of the French strategy to decrease tobacco use. In 2016, France started implementing a far-reaching strategy to tackle tobacco consumption. Increase in the price of tobacco products, support to stop smoking and actions to ‘de-normalise’ tobacco use are among the key pillars of this strategy.

Following the implementation of the strategy, the number of tobacco users in France decreased by 12%. Working together with Santé Publique France, the OECD is evaluating the health and economic impact of this policy package.

The OECD model is being used to understand how the reduction in tobacco use will decrease the future incidence of chronic diseases caused by tobacco – e.g. cancers and cardiovascular diseases – and how this decrease in morbidity will translate into a reduction in healthcare expenditure and increase in labour market outcomes.

**South Africa**

A precursor of the OECD SPHeP-NCD model was used to inform the preparation of the National Strategy for the Prevention and Control of Obesity in South Africa (2015-2020). High prevalence of overweight and its related risk factors, such as unhealthy diet and lack of physical activity, are among the key factors affecting population health in South Africa, and are responsible for almost 15% of the total burden of disease in the country.

Analyses based on the model supported South Africa in the preparation of the National Strategy by producing evidence on the effectiveness and cost-effectiveness of various policy options to promote healthier lifestyles. Findings from the model were incorporated in the National Strategy to provide a rationale supporting the various policy choices.
4 Publications related to OECD modelling work

OECD Flagship Publications

OECD (2021), Alcohol publication (title TBC), forthcoming.


Other Publications


All images © Shutterstock.com unless indicated otherwise.
For more information on the SPHeP models and to explore their results, please go to: http://oecdpublichealthexplorer.org/, or https://oe.cd/publichealth

Contact us:
Michele Cecchini
Principal Administrator for Public Health
Health Division, OECD
michele.ceccini@oecd.org